AKT1 and Parkinson disease: Further studies confirmed that OCN corrected motor dysfunction, inhibited the neuroinflammatory responses, and reduced dopaminergic neuronal injury via the AKT/GSK3β signaling pathway in an animal model of PD (Guo et al., 2018).